- Home
- MREO vs PSBD Comparison
MREO vs PSBD Comparison
Compare MREO & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MREO | PSBD |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 386.6M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | MREO | PSBD |
|---|---|---|
| Price | $2.02 | $11.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | $7.20 | ★ $13.30 |
| AVG Volume (30 Days) | ★ 2.4M | 94.7K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 14.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $131.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $11.51 |
| 52 Week High | $3.88 | $16.16 |
Technical Indicators
Market Signals| Indicator | MREO | PSBD |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 42.29 |
| Support Level | $1.89 | $11.77 |
| Resistance Level | $2.37 | $12.17 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 40.48 | 29.69 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.